To demonstrate that eribulin-induced pericyte phenotype switching can occur in human breast cancer, we employed specimens from the SOLTI-1007 trial of single agent, neoadjuvant eribulin treatment (NCT01669252, 1.4 mg/m2 eribulin i.v. on days 1 and 8 every 21-day cycle, for a total of 4 cycles) for HER2-negative breast cancer (n = 174; n = 73 TNBC, n = 101 hormone receptor-positive, HR+) (De Mattos-Arruda et al, 2021; Pascual et al, 2021). This evidence concerns the gene ERBB2 and breast cancer.